ClinicalTrials.Veeva

Menu

PSMA-RLT in Biochemically Recurrent PCa

Medical University of Vienna logo

Medical University of Vienna

Status and phase

Enrolling
Phase 2

Conditions

Prostate Cancer Recurrent

Treatments

Drug: [177Lu]Lu-PSMA I&T

Study type

Interventional

Funder types

Other

Identifiers

NCT06220188
1938/2022
2022-003713-11 (EudraCT Number)

Details and patient eligibility

About

Prospective single-center one-arm phase II study in patients with prostate cancer and confirmed biochemical recurrence (BCR) with PSA of ≥ 0.2 ng/ml after radical prostatectomy (RP) or PSA > nadir + 2ng/ml after radiotherapy (RT) but not radio-morphological local recurrence after primary therapy with curative intent receive systemic therapy with only 2 cycles of highly standardized (3 GBq in first cycle and 6 GBq in the second cycle) PSMA-RLT at 6-week intervals.

Enrollment

20 estimated patients

Sex

Male

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with biochemical recurrence after radical prostatectomy and radiotherapy with a PSA doubling-time (DT) of ≤ 12 months.
  • No hormonal therapy within the last 12 months or recovered testosterone levels.
  • PSMA PET negative result for local recurrence; presence of distant metastases is allowed: (cN0, cM0/cM1).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
  • Patients must have adequate bone marrow reserve: WBC ≥1.5 x 109 /L, Platelets ≥100 x 109 /L and Haemoglobin ≥9 g/dL.
  • Patients must have adequate renal function with eGFR ≥ 50mL/min/1.73m2 using the Modification of Diet Renal Disease (MDRD) equation and an Albumin level of ≥2.5 g/dL.
  • Patients must be able to sign Informed Consent Form.

Exclusion criteria

  • Concomitant participation in any other interventional trial.
  • Concurrent severe oncological and medical conditions that result in patients not having a life expectancy of longer than one year.
  • Presence of clinically relevant somatic or psychiatric diseases that might interfere with the objectives and assessments of the study.
  • Complete urinary out-flow obstruction or severe unmanageable urinary incontinence.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Biochemical recurrent prostate cancer but not radio-morphological local recurrence
Experimental group
Description:
Patients with prostate cancer and confirmed biochemical recurrence with PSA of ≥ 0.2 ng/ml after radical prostatectomy or PSA > nadir + 2ng/ml after radiotherapy but not radio-morphological local recurrence after primary therapy with curative intent will receive systemic therapy with [177Lu]Lu-PSMAI&T radioligand therapy
Treatment:
Drug: [177Lu]Lu-PSMA I&T

Trial contacts and locations

1

Loading...

Central trial contact

Sazan Rasul, PhD; Shahrokh F. Shariat, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems